

CROWN-7 Year Follow-Up

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study

Shaw AT, Solomon BJ, Felip E, et al. *Ann Oncol*. 2026:S0923-7534(26)00876-8. doi: 10.1016/j.annonc.2026.05.692




ANNENBERG CENTER FOR HEALTH SCIENCES


AT EISENHOWER

Imparting knowledge. Improving patient care.

CROWN-7 Year Analysis: Lorlatinib 100mg vs. Crizotinib 250mg



CROWN: Progression-Free Survival (ITT)



CROWN-7 Year Analysis: Safety

Key Adverse Events (Grade ≥ 3)	Lorlatinib (n=149)	Crizotinib (n=147)
Hypercholesterolemia	73% (22%)	4% (0%)
Hypertriglyceridemia	71% (26%)	6% (0%)
Edema	58% (5%)	43% (1%)
Peripheral neuropathy	46% (1%)	16% (1%)
Weight increase	45% (24%)	13% (2%)
Cognitive effects	30% (3%)	7% (0%)
Hypertension	28% (13%)	4% (1%)
Diarrhea	23% (2%)	54% (1%)
Grade ≥ 3 TRAEs	67%	39%
Discontinuations due to TRAEs	5%	6%

TRAE, treatment-related adverse events



ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER
Imparting knowledge. Improving patient care.

© Copyright 2025 Annenberg Center for Health Sciences | All Rights Reserved

Shaw AT, et al. *Ann Oncol*. 2026:S0923-7534(26)00876-8.